Vireo Growth to Acquire Planet 13 in All-Stock Merger Deal

Transaction Structure and Exchange Ratio

Planet 13 shareholders will receive a fixed exchange ratio of Vireo common stock, valued at approximately $187 million based on Vireo's July 26 closing price. The deal is structured as a tax-free reorganization under Section 368(a) of the Internal Revenue Code, a common vehicle for cannabis M&A given the prohibition on ordinary-course deductions under IRC §280E. On a strict reading of the merger agreement filed with the SEC, the exchange ratio is 0.135 shares of Vireo for each Planet 13 share. That implies a 22% premium to Planet 13's 30-day volume-weighted average price.

Vireo will assume Planet 13's outstanding debt obligations, totaling $41.3 million as of the company's most recent 10-Q filing. The combined entity will operate under the Vireo Growth name and retain Vireo's existing management team, with Planet 13 CEO Larry Scheffler joining the board as a non-executive director.

Retail and Cultivation Footprint Post-Merger

The combined company will control 47 dispensary licenses across six states and approximately 420,000 square feet of cultivation canopy. Planet 13's flagship Las Vegas SuperStore—a 112,000-square-foot tourist-destination dispensary on the Strip—will remain the anchor retail asset. Vireo operates 14 medical dispensaries in Minnesota, Maryland, and New York under state-specific vertical-integration frameworks that restrict the number of licenses per operator.

The merger creates operational redundancy in Nevada. Both companies hold cultivation and retail licenses there. Vireo has indicated it'll consolidate Nevada cultivation into Planet 13's existing 40,000-square-foot facility in Las Vegas and evaluate the disposition of duplicate retail licenses to comply with state ownership caps. Nevada law limits a single entity to 10 retail licenses statewide, and the combined footprint exceeds that threshold by three licenses.

280E Tax Efficiency and Pro Forma EBITDA

Vireo projects $14.2 million in annual cost synergies by consolidating cultivation, procurement, and compliance functions, with the majority of savings flowing to adjusted EBITDA rather than taxable income due to 280E limitations. Under IRC §280E, cannabis operators may deduct only cost of goods sold, not operating expenses. The merger allows the combined entity to allocate a greater share of overhead to COGS through vertical integration, reducing the effective 280E penalty.

Pro forma trailing-twelve-month revenue for the combined entity is $289 million, with adjusted EBITDA of $37.4 million. Vireo's investor presentation projects the merged company will achieve a 15.8% EBITDA margin by fiscal year 2027, compared to Vireo's standalone margin of 11.2% and Planet 13's margin of 18.6% as of Q2 2026. The delta reflects Planet 13's higher-margin tourist retail model versus Vireo's medical-focused operations, which carry lower per-transaction revenue but higher compliance overhead.

Regulatory Approval Timeline and Shareholder Vote

The transaction requires approval from the Nevada Cannabis Compliance Board, the California Department of Cannabis Control, and the Illinois Department of Financial and Professional Regulation, with regulatory filings submitted concurrently with the merger announcement. Nevada's CCB has a statutory 90-day review period for change-of-control applications, though the agency has historically extended that window for multi-jurisdiction operators. California's DCC requires a separate owner application for each license transferred. That adds procedural lag.

Planet 13 shareholders will vote on the merger at a special meeting scheduled for September 18, 2026. The transaction requires approval by a simple majority of shares voted. Vireo's board has authorized the issuance of up to 42 million new shares to fund the exchange, which will dilute existing Vireo shareholders by approximately 31% on a fully diluted basis. Vireo doesn't require a shareholder vote under Canadian Securities Exchange rules, as the dilution falls below the 50% threshold that triggers mandatory approval. For additional context on the regulatory variables in multi-state cannabis M&A, see the CannIntel topic hub on the Vireo-Planet 13 merger.